Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
Progress in neuro-psychopharmacology & biological psychiatry December 20, 2022 John Cook, Angelos Halaris
Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019. It antagonizes the NMDA receptor providing rapid improvement in symptoms with a complex mechanism of action primarily mediated through glutamatergic activation. Significant barriers exist to widespread use of esketamine including durability of response, particularly in the...